Atara Biotherapeutics, Inc. (ATRA) stock
ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.70−0.23 (-2.90%)
Close on Nov 13, 2026Market cap $77.29MP/E –Yield –
Atara Biotherapeutics total assets
Total assets on the balance sheet at the end of each period.
Atara Biotherapeutics's total assets was $18.61M at Sep 30, 2026. For fiscal 2025 it was $20.24M, down 81.5% from the year before. Over ten years it grew -24.2% a year on average. The highest annual figure on record is $588.12M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.24M | -81.5% |
| FY2024 | Dec 31, 2024 | $109.10M | -34.1% |
| FY2023 | Dec 31, 2023 | $165.50M | -56.0% |
| FY2022 | Dec 31, 2022 | $376.42M | -19.6% |
| FY2021 | Dec 31, 2021 | $468.13M | -20.4% |
| FY2020 | Dec 31, 2020 | $588.12M | +71.5% |
| FY2019 | Dec 31, 2019 | $342.94M | -12.5% |
| FY2018 | Dec 31, 2018 | $391.84M | +79.9% |
| FY2017 | Dec 31, 2017 | $217.78M | -17.5% |
| FY2016 | Dec 31, 2016 | $263.91M | -18.8% |
| FY2015 | Dec 31, 2015 | $324.98M | +206.2% |
| FY2014 | Dec 31, 2014 | $106.12M | +104.8% |
| FY2013 | Dec 31, 2013 | $51.83M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $18.61M | -38.3% |
| Q2 FY2026 | Jun 30, 2026 | $21.02M | -43.0% |
| Q1 FY2026 | Mar 31, 2026 | $20.00M | -67.8% |
| Q4 FY2025 | Dec 31, 2025 | $20.24M | -81.5% |
| Q3 FY2025 | Sep 30, 2025 | $30.17M | -78.9% |
| Q2 FY2025 | Jun 30, 2025 | $36.90M | -68.5% |
| Q1 FY2025 | Mar 31, 2025 | $62.04M | -62.5% |
| Q4 FY2024 | Dec 31, 2024 | $109.10M | -34.1% |
| Q3 FY2024 | Sep 30, 2024 | $142.71M | -24.4% |
| Q2 FY2024 | Jun 30, 2024 | $117.28M | -52.4% |
| Q1 FY2024 | Mar 31, 2024 | $165.27M | -45.3% |
| Q4 FY2023 | Dec 31, 2023 | $165.50M | -56.0% |
| Q3 FY2023 | Sep 30, 2023 | $188.79M | -48.7% |
| Q2 FY2023 | Jun 30, 2023 | $246.44M | -43.5% |
| Q1 FY2023 | Mar 31, 2023 | $302.08M | -24.0% |
| Q4 FY2022 | Dec 31, 2022 | $376.42M | -19.6% |
| Q3 FY2022 | Sep 30, 2022 | $368.32M | -18.1% |
| Q2 FY2022 | Jun 30, 2022 | $436.12M | -4.5% |
| Q1 FY2022 | Mar 31, 2022 | $397.28M | -25.0% |
| Q4 FY2021 | Dec 31, 2021 | $468.13M | -20.4% |
| Q3 FY2021 | Sep 30, 2021 | $449.92M | +10.9% |
| Q2 FY2021 | Jun 30, 2021 | $456.79M | +6.7% |
| Q1 FY2021 | Mar 31, 2021 | $529.64M | +76.8% |
| Q4 FY2020 | Dec 31, 2020 | $588.12M | +71.5% |
| Q3 FY2020 | Sep 30, 2020 | $405.53M | +11.2% |
| Q2 FY2020 | Jun 30, 2020 | $428.11M | +56.2% |
| Q1 FY2020 | Mar 31, 2020 | $299.55M | -7.8% |
| Q4 FY2019 | Dec 31, 2019 | $342.94M | -12.5% |
| Q3 FY2019 | Sep 30, 2019 | $364.79M | -17.6% |
| Q2 FY2019 | Jun 30, 2019 | $274.14M | -44.4% |
| Q1 FY2019 | Mar 31, 2019 | $324.73M | -31.4% |
| Q4 FY2018 | Dec 31, 2018 | $391.84M | +79.9% |
| Q3 FY2018 | Sep 30, 2018 | $442.94M | +92.8% |
| Q2 FY2018 | Jun 30, 2018 | $492.71M | +101.8% |
| Q1 FY2018 | Mar 31, 2018 | $473.11M | +95.7% |
| Q4 FY2017 | Dec 31, 2017 | $217.78M | -17.5% |
| Q3 FY2017 | Sep 30, 2017 | $229.69M | – |
| Q2 FY2017 | Jun 30, 2017 | $244.16M | – |
| Q1 FY2017 | Mar 31, 2017 | $241.74M | – |
| Q4 FY2016 | Dec 31, 2016 | $263.91M | – |
See a number that looks wrong?